Policy brief: Prenatal Cannabis Exposure and Foetal Neurodevelopment

Details: Published: 14 July 2026; Hits: 19

Overview

Recent human evidence adds weight to longstanding concerns that cannabis use during pregnancy can interfere with foetal brain development in biologically meaningful ways. The 2026 study by Ugartemendia and colleagues links prenatal cannabis exposure with altered cannabinoid signalling, altered dopamine-related signalling, and shifts in regulatory microRNAs in the developing human brain, with stronger effects in male foetuses.

These findings should be treated as a serious public health warning rather than a minor uncertainty. When a substance is associated with measurable changes in receptor systems and gene regulators that help organise brain maturation, the prudent policy position is prevention, not reassurance.

Why this matters

The study found reduced CB1 receptor levels in exposed foetal brains, especially in males, alongside increased D2 receptor levels and altered microRNAs involved in regulating both systems. This is concerning because the endocannabinoid system is not a peripheral or optional pathway in development; it is involved in neuronal migration, synapse formation, and the timing of early brain wiring.

Dopamine signalling is also central to later learning, motivation, attention, and behavioural regulation. Disturbance during foetal development raises concern not only about birth outcomes, but about later neurodevelopmental vulnerabilities that may only become visible in infancy, childhood, or adolescence.

Key concern for policy

The most troubling implication is that prenatal cannabis exposure may be shaping the architecture of the brain before birth. The observed male-skewed vulnerability is particularly significant because it offers a plausible biological pathway for sex-differentiated neurodevelopmental harms and supports a more precautionary approach to maternal cannabis use.

The same study also found that brain-derived extracellular vesicles isolated from maternal blood reflected many of the foetal-brain changes. That finding matters because it suggests foetal neurodevelopmental disturbance may be detectable through non-invasive maternal blood biomarkers, expanding both research and future screening possibilities.

Supporting public health context

Published research targeting pregnant and breastfeeding women argue that cannabis, including cannabidiol products, should not be treated as harmless in pregnancy and stress that THC crosses the placenta and may affect the developing baby. The evidence continues to frame cannabis use during pregnancy as a serious child-development issue and points to accumulating concern about adverse developmental effects.

Although advocacy sources should not substitute for primary research, they are useful for translating an increasingly consistent cautionary message into public-facing health communication. In this case, the underlying direction of travel is reinforced by peer-reviewed evidence and broader reviews linking prenatal cannabis exposure with developmental, cognitive, and behavioural risks.

Policy implications

Public health guidance should clearly advise that no form of cannabis, including high-THC products and CBD-containing preparations, can be assumed safe during pregnancy or breastfeeding.
Antenatal care should include routine, non-stigmatising screening and brief intervention regarding cannabis use, with special attention to the false belief that cannabis is a natural or safer remedy for pregnancy-related symptoms.
Health departments should update consumer messaging to reflect emerging human molecular evidence, not just older observational or animal literature.
Research investment should prioritise longitudinal follow-up and biomarker validation, particularly given the possibility of non-invasive detection through maternal blood samples.

Conclusion

The policy message is increasingly difficult to soften: prenatal cannabis exposure is not a neutral lifestyle choice. The emerging evidence indicates that it may alter core signalling systems involved in foetal brain development, with potentially serious and sex-specific consequences that justify stronger prevention messaging and more explicit clinical guidance.

References

By Dalgarno Institute.